"We observed seemingly higher apparel clearance inventory at TGT and deeper markdowns (30-70%) plus an extra 20% off," ...

One person found a $6.99 TJ Maxx teapot retailing for $7.37 at Goodwill and another reported on a $6 Target purse priced at ...

Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in ...

Chevron's strategic moves and positive developments position the company for growth and success, making it a strong choice ...

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or ...

Alarm bells over Democratic vice presidential candidate Tim Walz’s deep ties to China are stirring debate on national ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Brokerage firms have given a mixed reaction to the shares of drug maker CIPLA Ltd. The pharma company announced its results ...

QIAGEN is expanding its portfolio for QIAstat-Dx in North America, with the recent launch of the QIAstat-Dx Analyzer 2.0, FDA clearance of the Gastrointestinal Panel 2 and submission for FDA clearance ...

Cipla share price had fallen after the company's September quarter results as analysts cut their target price, citing weaker than expected domestic business and challenges in its key products.

Cipla projects a mid-FY26 launch for Advair, while the release of Abraxane is contingent on regulatory clearance of the company's Goa facility. Respiratory drug Albuterol faces intensifying ...

The clearance of Cipla's Goa facility opens the doors for the launch of Abraxane, which could be a around $120 million opportunity at peak.